

Clearside Biomedical to Participate in Upcoming Investor Events in November and December 2021

November 11, 2021

ALPHARETTA, Ga., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS[®]), announced today that it will participate in the following investor events, which will each be held in a virtual meeting format:

Stifel 2021 Virtual Healthcare Conference

Wednesday, November 17, 2021 at 8:00 am ET

Piper Sandler 33rd Annual Virtual Healthcare Conference

Monday, November 29 - Thursday, December 2, 2021

Recorded Presentation will be available: Monday, November 22, 2021, at 10:00 a.m. ET

BTIG Ophthalmology Day

Tuesday, November 30, 2021

UBS Ophthalmology Day

Monday, December 6, 2021

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside's SCS injection platform, utilizing the Company's proprietary SCS Microinjector ®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside's first product, XIPERE TM (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin Remy Bernarda ir@clearsidebio.com (678) 430-8206

Source: Clearside Biomedical, Inc.